Researchers Identify New Drug Candidate UR214-9 That Targets Septin Structures in Ovarian and Other Cancers
Scientists discovered that a small molecule called UR214-9 can disrupt septin protein structures in ovarian cancer cells and showed promise in reducing tumor growth in multiple cancer types. Septins are cytoskeletal proteins that form complex structures in cancer cells, and previous lack of tools made studying them difficult. This finding could lead to new cancer treatments targeting a previously underexplored cellular component.
Researchers developed an in-vitro system to study septin higher-order structures in ovarian cancer cells and tested the compound UR214-9 against them. The drug works by disrupting how septin proteins assemble into their normal octamer structures, causing them to reorganize into abnormal aggregates and filaments. In cell culture and animal models, UR214-9 reduced growth of ovarian, endometrial, breast, and pancreatic cancer xenografts while showing acceptable safety profiles. The compound affected cancer cell proliferation, adhesion, invasion, and migration without significantly disrupting other cellular processes like ceramide transport. This research identifies septins as a druggable target for multiple cancer types and provides a new tool for studying septin biology.
What's missing
The article does not discuss the stage of drug development, timeline to clinical trials, or how UR214-9 compares to existing cancer treatments. Additionally, there is no information about potential limitations of the in-vitro model or whether the animal safety data translates to human safety.
How coverage differed
This is a preprint from bioRxiv, which presents preliminary research findings. The source uses technical scientific language and focuses on mechanistic details and experimental methodology, which is standard for academic research communication but may overstate significance before peer review and clinical validation.
What different sources said
- bioRxivCenter
Reconstruction of septin higher-order nano-size structures in ovarian cancer cells uncover susceptibility to the septin-targeting small molecule UR214-9
Related
Experimental compound T2 shows promise in limiting breast cancer progression in mouse model
Researchers found that thiosemicarbazone T2, an experimental compound, suppressed cancer progression in a mouse model of triple-negative breast cancer by blocking a key cellular signaling pathway. The study used an immunocompetent mouse model that mimics how human breast cancer progresses from non-invasive to invasive forms. The findings suggest T2 could warrant further investigation as a potential treatment for this aggressive form of breast cancer.
Scientists Develop Cost-Effective Method to Extract Protein from Dried Leafy Vegetables
Researchers have developed a simple, scalable process to extract RuBisCO, Earth's most abundant protein, from dried leafy biomass like spinach, kale, and rocket. The method achieves approximately 70-90% extraction efficiency without resource-intensive processing, addressing a gap since most existing extraction techniques were designed for fresh material. This advancement could enable sustainable plant protein production from agricultural waste, supporting circular economy approaches in food supply chains.
Researchers Observe Synchronized Quantum Interactions Between Excitons and Phonons in Perovskite Nanocrystals
An international research team directly observed coherent quantum interactions between excitons (light-induced electronic excitations) and phonons (crystal lattice vibrations) in perovskite nanocrystals. This advance in understanding quantum dynamics in semiconductor materials was published in Nature Communications. The findings could improve understanding of energy transfer processes in quantum materials with applications in optoelectronics and quantum computing.